A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer

Gagno, Sara; Poletto, Elena; Bartoletti, Michele; Quartuccio, Luca; Romualdi, Chiara; Garziera, Marica; Scalone, Simona; Sorio, Roberto; Dreussi, Eva; Zanusso, Chiara; Mattia, Elena De; Roncato, Rossana; Cecchin, Erika; Giorda, Giorgio; Vita, Salvatore De; Bo, Michele Dal; Puglisi, Fabio; Toffoli, Giuseppe

doi:10.1016/j.ygyno.2019.10.019

Cited by 6 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two hundred and thirty high-stage (III-IV), high-grade (G2-G3) advanced EOC patients were retrospectively included in this study. Clinical and demographic characteristics of the study population were previously described [14] and are reported in Table 1. Briefly, all patients were aged ≥18 years, had histologically confirmed diagnosis of EOC and provided written informed consent for the use of peripheral blood and clinical data for research purposes.…”

Section: Patientsmentioning

confidence: 99%

“…Polymorphisms were genotyped with Automated Fragment Analysis on Genetic Analyzer ABI PRISM 3100 (Applied Biosystems, CA, USA), TaqMan R Assays on 7500 Real-Time PCR System (Applied Biosystems), PSQ96 MA Pyrosequencing (Biotage AB, Uppsala, Sweden) or a custom-designed Illumina GoldenGate Assay on a BeadXpress R Reader (Illumina, CA, USA) as previously reported [14]. PCR amplifications were performed in an Eppendorf Mastercycler gradient (Eppendorf, Milan, Italy), with TaqGold DNA Polymerase (Applied Biosystems).…”

Section: Gene Variants and Genotypingmentioning

confidence: 99%

“…As previously described [14], there were 230 recruited subjects, all of Caucasian origin (self-reported). The majority of patients (76%) was affected by a stage III high-grade serous disease.…”

Section: Patients and Clinical Outcomementioning

confidence: 99%

“…ABCG2 rs3219191 was associated with a decreased risk of death (HR: 0.77; 95% CI: 0.60-0.98; p = 0.036), progression (HR: 0.77; 95% CI: 0.62-0.97; p = 0.0251) and platinum resistance (HR: 0.74; 95% CI: 0.59-0.93; p = 0.0091). Accordingly, its CTCA insertion allele was linked to an increasingly improved median survival time (median OS: Del/Del = 36 months, Ins/Del = 52 [43-not reached] months, Ins/Ins = 56 [48-not reached] months), to a longer PFS (median PFS: Del/Del = 16 [12][13][14][15][16][17][18][19] months, Ins/Del = 17 [15][16][17][18][19][20][21][22] months, Ins/Ins = 19 [17][18][19][20][21][22][23][24][25][26][27][28][29] ). The other two polymorphisms were both located in the UGT1A locus and were associated with a higher risk of death, progression and platinum resistance.…”

Section: Polymorphisms' Association With the Clinical Outcomesmentioning

confidence: 99%

“…Thus, the combination of the small-size deleterious effects of polymorphisms on genes involved in different pathways regulating the same process may enhance the predictive and prognostic power of PGx biomarkers. In our previous work [14], this strategy was successfully applied in a population of 230 EOC patients, leading to the definition of an immunogenetic score able to stratify patients according to their overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Pharmacogenetic Score Predicts Overall Survival, Progression-Free Survival and Platinum Sensitivity in Ovarian Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI). Results: ABCG2 rs3219191D>I, UGT1A rs10929302G>A and UGT1A rs2741045T>C polymorphisms were significantly associated with all three parameters (OS, PFS and PFI) and were used to generate a score. Patients in high-risk group had a poorer OS (hazard ratio [HR]: 1.8; 95% CI: 1.3–2.7; p = 0.0019), PFS (HR: 2.0; 95% CI: 1.4–2.9; p < 0.0001) and PFI (HR: 1.9; 95% CI: 1.4–2.8; p = 0.0002) compared with those in low-risk group. Conclusion: The prognostic-score including polymorphisms involved in drug and estrogen pathways stratifies OCP according to OS, PFS and PFI.

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Gene Variants and Genotypingmentioning

confidence: 99%

Section: Patients and Clinical Outcomementioning

confidence: 99%

Section: Polymorphisms' Association With the Clinical Outcomesmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Pharmacogenetic Score Predicts Overall Survival, Progression-Free Survival and Platinum Sensitivity in Ovarian Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer

Suzuki,

Yokoi,

Matsuzaki

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundPlatinum chemotherapy is the cornerstone of treatment for high‐grade serous ovarian cancer (HGSOC); however, validated biomarkers that can accurately predict platinum response are lacking. Based on their roles in the underlying pathophysiology, circulating microRNAs are potential, noninvasive biomarkers in cancer. In the present study, we aimed to evaluate the circulating miRNA profiles of patients with HGSOC and to assess their potential utility as biomarkers to predict platinum response.MethodsPretreatment serum samples collected from patients who received platinum chemotherapy for Stage III–IV HGSOC between 2008 and 2016 were analyzed using miRNA microarray. LASSO logistic regression analysis was used to construct predictive models for treatment‐free interval of platinum (TFIp).ResultsThe median follow‐up was 54.6 (range, 3.5–144.1) months. The comprehensive analysis of 2588 miRNAs was performed in serum samples of 153 eligible patients, and predictive models were constructed using a combination of circulating miRNAs with an area under the receiver operating characteristic curve of 0.944 for TFIp >1 month, 0.637 for TFIp ≥6 months, 0.705 for TFIp ≥12 months, and 0.938 for TFIp ≥36 months. Each predictive model provided a significant TFIp classification (p = 0.001 in TFIp >1 month, p = 0.013 in TFIp ≥6 months, p < 0.001 in TFIp ≥12 months, and p < 0.001 in TFIp ≥36 months).ConclusionCirculating miRNA profiles has potential utility in predicting platinum response in patients with HGSOC and can aid clinicians in choosing appropriate treatment strategies.

show abstract

Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer

Suzuki,

Yokoi,

Matsuzaki

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Platinum chemotherapy is the cornerstone of treatment for high–grade serous ovarian cancer (HGSOC); however, validated biomarkers that can accurately predict platinum response are lacking. Based on their roles in the underlying pathophysiology, circulating microRNAs are potential, noninvasive biomarkers in cancer. In the present study, we aimed to evaluate the circulating miRNA profiles of patients with HGSOC and to assess their potential utility as biomarkers to predict platinum response. Methods: Pretreatment serum samples collected from patients who received platinum chemotherapy for stage III–IV HGSOC between 2008 and 2016 were analyzed using miRNA microarray. LASSO logistic regression analysis was used to construct predictive models for treatment–free interval of platinum (TFIp). Results: The median follow–up was 54.6 (range, 3.5–144.1) months. The comprehensive analysis of 2,588 miRNAs was performed in serum samples of 153 eligible patients, and predictive models were constructed using a combination of circulating miRNAs with an area under the receiver operating characteristic curve of 0.944 for TFIp > 1 month, 0.637 for TFIp ≥ 6 months, 0.705 for TFIp ≥ 12 months, and 0.938 for TFIp ≥ 36 months. Each predictive model provided a significant TFIp classification (p = 0.001 in TFIp >1 month, p = 0.013 in TFIp ≥ 6 months, p < 0.001 in TFIp ≥ 12 months, and p < 0.001 in TFIp ≥ 36 months). Conclusion: Circulating miRNA profiles has potential utility in predicting platinum response in patients with HGSOC and can aid clinicians in choosing appropriate treatment strategies.

show abstract

A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer

Cited by 6 publications

References 40 publications

Pharmacogenetic Score Predicts Overall Survival, Progression-Free Survival and Platinum Sensitivity in Ovarian Cancer

Pharmacogenetic Score Predicts Overall Survival, Progression-Free Survival and Platinum Sensitivity in Ovarian Cancer

Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer

Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer

Contact Info

Product

Resources

About